StemBioSys

8 articles about StemBioSys

• StemBioSys Announces Launch of CELLvo™ Atrial Cardiomyocyte, a Technological Leap Forward in Cardiotoxicity Screening

  6/13/2023

  StemBioSys, Inc. announced the launch of CELLvo™ Atrial Cardiomyocyte, a "chamber specific" human induced pluripotent stem cell derived cardiomyocyte designed to function identically to human atrial cardiomyocytes.

• StemBioSys Announces Launch of NeuroMatrix™, a Technological Leap Forward in Laboratory Production of Functionally Mature Human Neural Cell Types

  2/13/2023

  StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types.

• StemBioSys, Inc. to Participate in Biotech Showcase Digital During "J.P. Morgan Week 2021"

  12/16/2020

   StemBioSys, Inc., a privately held biomedical company that manufactures and develops innovative, advanced human stem cell technologies to improve the predictive power of pre-clinical drug safety screening, today announced its President and Chief Executive Officer Bob Hutchens will participate in Biotech Showcase Digital bei

• How This Senior Scientist Got A Job At StemBioSys

  3/30/2017

• StemBioSys Release: Company Announces U.S. And Canadian Distribution Agreement With VWR International, Inc.

  1/18/2017

• StemBioSys Closes $8 Million Series A Financing

  4/14/2015

• StemBioSys To Present At Biotech Showcase™ 2015

  1/7/2015

• CEO Shakeup At San Antonio Biotech Company StemBioSys

  5/23/2014